看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。3 x* V, Q1 w2 _7 U
2 j( i' n& v% n( u. M: k! A0 s) G: ]
Currently available feasibility data for possible combination strategies. ' X8 q5 P' ?8 H9 f9 g- k) N% P; @6 h }
————————————————————————————————( m# G. [! S. v& F1 D/ M
Combination Feasibility according to preliminary data 7 C5 D# x* N* y ]
——————————————————————————————————
7 k1 L7 }# S# f1 K! M9 I6 @ wBevacizumab + sorafenib Yes, reduced dose
: l; n( [+ W) I" f( N" CBevacizumab + sunitinib† No : i+ r' v1 [! z6 J% d
Bevacizumab + temsirolimus Yes 1 H; R8 t1 A! u9 r3 `" n. M3 c3 V
Bevacizumab + everolimus Yes
& u; s( X6 |$ [% y9 d9 pSorafenib + sunitinib ? 3 z" x9 s, ^8 K3 E
Sorafenib + temsirolimus Yes, reduced dose ( W# G( _! l+ c4 l0 K# ?
Sorafenib + everolimus Yes, reduced dose 8 c. C, q9 m% } e
Sunitinib + temsirolimus† No ) b# P1 [) Z u6 |7 M. j2 M
Sunitinib + everolimus ?
2 \* ^4 S7 y! e+ zTemsirolimus + everolimus ? : W! y2 V" L1 v% y o* \
————————————————————
2 r, @5 S, X# |8 E% e9 O% Q' h6 }†Led to US FDA warning.% k0 G, |+ ^! Y7 H7 u) J9 W' j/ T
?: As yet unattempted combination.- c, p0 ` u; P0 f* M
|